Autoimmune Hepatitis

Fatima Safira Alatas (Department of Child Health, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia)
Gryselda Hanafi (Department of Child Health, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia)
Lestari Kanti Wilujeng (Department of Child Health, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia)
Nielda Kezia Sumbung (Department of Child Health, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia)

Archives of Pediatric Gastroenterology, Hepatology, and Nutrition
Vol. 1 No. 1 (2022): APGHN Vol. 1 No. 1 May 2022

Autoimmune hepatitis (AIH) is a condition caused by self-perpetuating immune response towards hepatocytes in liver. In children, AIH may progressed more rapidly compared to adults. Thus, early diagnosis and prompt treatment are the key for successful management of AIH. Five main characteristics of AIH include female predominance, increased IgG or hypergammaglobulinemia, circulatory autoantibody seropositivity, and hepatitis interface from the histological finding. Liver biopsy is needed to evaluate the degree of damage and to confirm the diagnosis. The standard regiment for AIH include prednisone (or prednisolone) and azathioprine. Other alternative treatments available for non-responder, such as mycophenolate mofetil, tacrolimus, cyclosporine, budesonide, rituximab, and infliximab. AIH treatment is recommended to be taken minimally for 2-3 years before attempting treatment termination.